Moreover, MEF2C expression seems to be BCBM-specific as almost no expression of this TF was observed when resected brain samples from glioma were analyzed as non-BCBM controls by focusing in regions with no reactive or neoplastic astrocytes and microglia to assure tissue integrity as much as possible. This evidence concerns the gene MEF2C and central nervous system cancer.